Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study

  1. V. Belcastro1,2,
  2. C. Costa1,3,
  3. F. Galletti1,
  4. F. Pisani2,
  5. P. Calabresi1,3,
  6. L. Parnetti1

Article first published online: 21 JUL 2007

DOI: 10.1111/j.1468-1331.2007.01907.x

Issue

European Journal of Neurology

European Journal of Neurology

Volume 14, Issue 10, pages 1176–1178, October 2007

Additional Information

How to Cite

Belcastro, V., Costa, C., Galletti, F., Pisani, F., Calabresi, P. and Parnetti, L. (2007), Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. European Journal of Neurology, 14: 1176–1178. doi: 10.1111/j.1468-1331.2007.01907.x

Author Information

  1. 1

    Clinica Neurologica, Università degli Studi di Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy

  2. 2

    Clinica Neurologica, Università degli Studi di Messina, Policlinico Universitario, Messina, Italy

  3. 3

    IRCCS Fondazione Santa Lucia, Rome, Italy

*Lucilla Parnetti, Clinica Neurologica, Università di Perugia, Ospedale S. Maria della Misericordia, S Andrea delle Fratte, 06156 Perugia, Italy (tel.: +39-075-5784228; fax +39-075-5784229; e-mail: parnetti@unipg.it).

Publication History

  1. Issue published online: 26 JUL 2007
  2. Article first published online: 21 JUL 2007
  3. Received 5 April 2007 Accepted 16 June 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (61K)

Keywords:

  • Alzheimer's disease;
  • antiepileptic drugs;
  • dementia;
  • late-onset seizures;
  • levetiracetam

Levetiracetam (LEV) monotherapy was investigated in 25 patients with advanced Alzheimer's disease (AD) and new-onset epileptic seizures in a prospective open-label study. At a daily dose of 1000–1500 mg, 72% were seizure-free for at least one year; 16% discontinued for untolerability; 8% were unresponsive; 4% were lost to follow-up. These results suggest the need for controlled studies to confirm if LEV can be a first-choice drug in AD.

View Full Article (HTML) Get PDF (61K)